Prostate cancer incidence and mortality trends in 37 European countries: An overview
Prostate cancer incidence and mortality trends in 37 European countries: An overview
复制标题
DOI：
10.1016/j.ejca.2010.09.013
复制
发表时间：
2010-11-01
影响因子：
8.4
通讯作者：
Auvinen, A.
中科院分区：
文献类型：
--
作者：
Bray, F.;Lortet-Tieulent, J.;Auvinen, A.
前列腺癌已成为欧洲男性中最常见的癌症，在过去二十年中发病率迅速上升。在有可比较数据的24个国家中，发病率一直在一致增加，尽管在少数发病率很高的国家（瑞典、芬兰和荷兰），发病率在过去3-4年中开始下降。前列腺癌死亡率最高的是波罗的海地区（爱沙尼亚、拉脱维亚和立陶宛）以及丹麦、挪威和瑞典。在所考虑的37个欧洲国家中，有13个国家的前列腺癌死亡率一直在下降，主要是在每个区域内资源较高的国家，首先是英格兰和威尔士（1992年），最近是捷克共和国（2004年）。每年下降的幅度有相当大的差异，从苏格兰（1994年以来）的约1%到匈牙利、法国和捷克共和国最近的4%以上的下降幅度不等。发病率增加的程度（1990年代末）与最近死亡率下降之间似乎没有什么关系。目前尚不清楚发病率的增加趋势在多大程度上表明了真正的风险，以及有多少是由于发现了潜伏性疾病。1990年以后死亡率的下降可能归因于治疗的改善和前列腺特异性抗原（PSA）检测的效果。波罗的海区域和几个中欧和东欧国家观察到的死亡率增加似乎反映了风险的实际增加，需要进一步监测。(C) 2010 Elsevier Ltd.版权所有。
Prostate cancer has emerged as the most frequent cancer amongst men in Europe, with incidence increasing rapidly over the past two decades. Incidence has been uniformly increasing in the 24 countries with comparable data available, although in a few countries with very high rates (Sweden, Finland and The Netherlands), incidence has begun to fall during the last 3-4 years. The highest prostate cancer mortality rates are in the Baltic region (Estonia, Latvia and Lithuania) and in Denmark, Norway and Sweden. Prostate cancer mortality has been decreasing in 13 of the 37 European countries considered - predominantly in higher-resource countries within each region - beginning in England and Wales (1992) and more recently in the Czech Republic (2004). There was considerable variability in the magnitude of the annual declines, varying from approximately 1% in Scotland (from 1994) to over 4% for the more recent declines in Hungary, France and the Czech Republic. There appears little relation between the extent of the increases in incidence (in the late 1990s) and the recent mortality declines. It remains unclear to what extent the increasing trends in incidence indicate true risk and how much is due to detection of latent disease. The decreasing mortality after 1990 may be attributable to improvements in treatment and to an effect of prostate specific antigen (PSA) testing. The increase in mortality observed in the Baltic region and in several Central and Eastern European countries appear to reflect a real increase in risk and requires further monitoring. (C) 2010 Elsevier Ltd. All rights reserved.